Chesapeake IRB Announces Acquisition of MaGil IRB
Columbia, Md., June 7, 2017 (Business Wire) – Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced it has acquired MaGil IRB, a central IRB located in Rockville, Md.
The MaGil acquisition provides Chesapeake with additional AAHRPP-accredited review capacity and a staff that broadens Chesapeake’s presence for CROs, pharmaceutical companies, and biotech companies. This marks Chesapeake’s fifth acquisition of an AAHRPP-accredited IRB since 2013, further positioning itself as an IRB to support the growth in the clinical research industry.
“Today we are delighted to welcome MaGil IRB to the Chesapeake family,” said Jeff Wendel, president and CEO of Chesapeake. “Together, we are even better positioned to deliver unparalleled human subject protections and oversight and exceptional client service.”
“Joining with Chesapeake allows MaGil customers to benefit from Chesapeake’s innovative cloud-based IRB platform, CIRBI, while continuing the joint mission of safeguarding the rights and welfare of clinical research participants,” said Gil Price, co-founder and CEO of MaGil IRB.
About Chesapeake IRB
Chesapeake IRB, an AAHRPP-accredited company, provides independent IRB submission and review services to pharmaceutical, biotech, and medical device companies, as well as academic medical centers and hospital systems. Its paperless, cloud-based submission and review platform, CIRBI, leads the field and has set the standard in review turnaround time, quality, and document accessibility. Headquartered in Columbia, MD, Chesapeake IRB has offices across the United States and a wholly owned subsidiary, IRB Services, with offices in Toronto and Montreal, Canada. Visit chesapeakeirb.com for more information.
CONTACT:
Lea Studer
SCORR Marketing
308.237.5567
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
